On January 20, 2026, GSK plc announced changes in ViiV Healthcare's shareholding structure, with Shionogi increasing its stake to 21.7% and GSK retaining 78.3%. The deal involves a $2.125 billion investment from Shionogi, simplifying ViiV's shareholder structure after Pfizer's exit and entails a special dividend of $250 million to GSK.